Allogene Therapeutics Ownership | Who Owns Allogene Therapeutics?


OverviewForecastFinancialsChartTranscripts

Allogene Therapeutics Ownership Summary


Allogene Therapeutics is owned by 74.18% institutional investors, 16.70% insiders, and 9.13% retail investors. Pfizer is the largest institutional shareholder, holding 10.06% of ALLO shares. American Funds SMALLCAP World A is the top mutual fund, with 5.10% of its assets in Allogene Therapeutics shares.

ALLO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAllogene Therapeutics74.18%16.70%9.13%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Pfizer22.03M10.06%$27.32M
Blackrock16.45M9.72%$38.32M
Tpg gp a18.72M8.55%$23.21M
Blackrock funding, inc. /de17.51M8.00%$21.72M
Vanguard group9.02M4.12%$11.19M
Primecap management co/ca/7.08M3.23%$8.78M
Woodline partners lp4.36M1.99%$5.41M
Frazier life sciences management3.87M1.77%$4.80M
Geode capital management3.83M1.75%$4.75M
Price t rowe associates inc /md/3.68M1.68%$4.56M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Vida ventures advisors1.80M7.59%$2.23M
Pfizer22.03M6.25%$27.32M
Wildcat capital management2.92M2.50%$3.62M
Tpg gp a18.72M1.26%$23.21M
Patient square capital lp2.98M0.99%$3.70M
Dafna capital management1.38M0.42%$1.71M
Harold davidson & associates295.43K0.17%$366.34K
Frazier life sciences management3.87M0.14%$4.80M
Lynx1 capital management lp546.12K0.14%$677.19K
Moloney securities asset management514.00K0.08%$637.36K

Top Buyers

HolderShares% AssetsChange
Blackrock16.45M0.00%6.79M
Two sigma investments, lp3.38M0.01%1.77M
Ubs group3.57M0.00%1.53M
Primecap management co/ca/7.08M0.01%1.36M
Renaissance2.89M0.00%1.22M

Top Sellers

HolderShares% AssetsChange
Capital world investors---11.15M
Lynx1 capital management lp546.12K0.14%-10.51M
Darwin global management---10.48M
Goldman sachs group1.20M0.00%-4.30M
Boxer capital---3.85M

New Positions

HolderShares% AssetsChangeValue
Jacobs levy equity management878.96K0.01%878.96K$2.05M
Australiansuper pty382.14K0.00%382.14K$473.86K
Bridgeway capital management250.00K0.01%250.00K$310.00K
Headlands139.96K0.01%139.96K$173.55K
Hrt financial lp132.53K0.00%132.53K$164.00K

Sold Out

HolderChange
Capital performance advisors llp-41.00
Raymond james financial-45.00
Dunhill financial-70.00
Pnc financial services group-85.00
Federation des caisses desjardins du quebec-100.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20251668.50%162,395,329-2.90%741.27%8526.87%37-11.90%
Jun 30, 2025160-6.98%183,929,908-6.69%841.00%66-27.47%4714.63%
Mar 31, 2025170-1.73%196,870,7584.48%911.13%90-2.17%41-
Dec 31, 20241655.10%185,488,00512.84%881.44%8927.14%40-11.11%
Sep 30, 2024156-8.77%164,386,704-0.47%780.82%71-24.47%459.76%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
American Funds SMALLCAP World A11.15M5.10%-1.12M
Fidelity Growth Compy Commingled Pl O4.58M2.19%-
Vanguard US Total Market Shares ETF4.34M2.00%-
Vanguard Total Stock Mkt Idx Inv4.19M1.90%-92.41K
Fidelity Select Health Care4.00M1.88%-350.00K
SPDR® S&P Biotech ETF3.90M1.84%-23.78K
Fidelity Series Small Cap Opps3.54M1.69%-141.30K
Vanguard Capital Opportunity Inv3.56M1.63%600.00K
iShares Russell 2000 ETF3.58M1.61%-
T. Rowe Price Health Sciences2.72M1.23%-30.52K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 17, 2025Beneski Benjamin Machinas SVP, Chief Technical OfficerSell$958.92
Oct 21, 2025Parker Geoffrey M. CHIEF FINANCIAL OFFICERSell$46.17K
Jun 10, 2025MESSEMER DEBORAH M.-Sell$52.38K
Apr 21, 2025Yoshiyama Annie SVP, FinanceSell$13.54K
Mar 14, 2025Chang David D President and CEOSell$91.47K

Insider Transactions Trends


DateBuySell
2025 Q4-2
2025 Q2-2
2025 Q1-9
2024 Q4-2
2024 Q3--

ALLO Ownership FAQ


Who Owns Allogene Therapeutics?

Allogene Therapeutics shareholders are primarily institutional investors at 74.18%, followed by 16.70% insiders and 9.12% retail investors. The average institutional ownership in Allogene Therapeutics's industry, Biotech Stocks , is 45.24%, which Allogene Therapeutics exceeds.

Who owns the most shares of Allogene Therapeutics?

Allogene Therapeutics’s largest shareholders are Pfizer (22.03M shares, 10.06%), Blackrock (16.45M shares, 9.72%), and Tpg gp a (18.72M shares, 8.55%). Together, they hold 28.34% of Allogene Therapeutics’s total shares outstanding.

Does Blackrock own Allogene Therapeutics?

Yes, BlackRock owns 9.72% of Allogene Therapeutics, totaling 16.45M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 38.32M$. In the last quarter, BlackRock increased its holdings by 6.79M shares, a 70.37% change.

Who is Allogene Therapeutics’s biggest shareholder by percentage of total assets invested?

Vida ventures advisors is Allogene Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.59% of its assets in 1.8M Allogene Therapeutics shares, valued at 2.23M$.

Who is the top mutual fund holder of Allogene Therapeutics shares?

American Funds SMALLCAP World A is the top mutual fund holder of Allogene Therapeutics shares, with 5.10% of its total shares outstanding invested in 11.15M Allogene Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools